|
Jul 26
|
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
|
|
Jun 26
|
Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety
|
|
May 21
|
Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
|
|
Mar 20
|
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
|
|
Mar 18
|
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
|
|
Dec 28
|
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
|
|
Oct 16
|
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
|
|
Aug 10
|
Silo Pharma Engages Clarivate for Intellectual Property and Patent Management
|
|
Aug 8
|
Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
|